Cisplatin at sub-toxic levels mediates integrin switch in lung cancer cells

Anticancer Research

Volumn 34, Issue 12, 2014, Pages 7111-7117

  Maiuthed, Arnatchai ^a   Chanvorachote, Pithi ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Cisplatin; Integrin; Lung cancer; Metastasis; Migration

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALPHA4 INTEGRIN; ALPHA5 INTEGRIN; BETA1 INTEGRIN; BETA3 INTEGRIN; BETA5 INTEGRIN; CISPLATIN; FOCAL ADHESION KINASE; GUANOSINE TRIPHOSPHATE; INTEGRIN; PHALLOIDIN; PROTEIN; PROTEIN KINASE B; RAC PROTEIN; REGULATOR PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHODAMINE; ALPHA INTEGRIN; ANTINEOPLASTIC AGENT; BETA INTEGRIN; RHO KINASE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG EFFECT; DRUG EXPOSURE; FILOPODIUM; GENE SWITCHING; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CANCER CELL LINE; MTT ASSAY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STAINING; WESTERN BLOTTING; WOUND HEALING; BIOSYNTHESIS; CELL ADHESION; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; LUNG NEOPLASMS; PHYSIOLOGY; PSEUDOPODIUM; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; INTEGRIN ALPHA CHAINS; INTEGRIN BETA CHAINS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PSEUDOPODIA; RAC GTP-BINDING PROTEINS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84918550224     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62(1): 10-29, 2012.
2. El Sharouni SY, Kal HB and Battermann JJ: Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy. Br J Cancer 89(12): 2184-2189, 2003.
3. Bourhis J, Wilson G, Wibault P, Janot F, Bosq J, Armand JP, Luboinski B, Malaise EP and Eschwege F: Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer. Laryngoscope 104(4): 468-472, 1994.
4. Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, Kumar J, Thompson EW, Quinn MA, Findlay JK and Ahmed N: Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J cell Biochem 112(10): 2850-2864, 2011.
5. Songserm T, Pongrakhananon V and Chanvorachote P: Sub-toxic cisplatin mediates anoikis resistance through hydrogen peroxideinduced caveolin-1 up-regulation in non-small cell lung cancer cells. Anticancer Res 32(5): 1659-1669, 2012.
6. Gutz S: Chemotherapy in cancer of the lung. MMW Fortschr Med 148(22): 33-34, 2006.
7. Moschos SJ, Drogowski LM, Reppert SL and Kirkwood JM: Integrins and cancer. Oncology 21(9 Suppl 3): 13-20, 2007.
8. Desgrosellier JS, Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10(1): 9-22, 2010.
9. Huttenlocher A and Horwitz AR: Integrins in cell migration. Cold Spring Harb Perspect Biol 3(9): a005074, 2011.
10. Stupack DG: The biology of integrins. Oncology 21(9 Suppl 3): 6-12, 2007.
11. Xue F, Janzen DM and Knecht DA: Contribution of Filopodia to Cell Migration: A Mechanical Link between Protrusion and Contraction. Int J Cell Biol 507821, 2010.
12. DAntonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, Fulvi A and de Marinis F: Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol 6(3): 101-114, 2014.
13. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
14. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M and Allgayer H: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in nonsmall cell lung cancer. Mol Cancer Res 8(9): 1207-1216, 2010.
15. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, Norton L, Brogi E and Massague J: A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150(1): 165-178, 2012.
16. Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam W. L, Ling V and Lam S: Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance. J Thorac oncol 8(2): 161-170, 2013.
17. Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69(1): 11-25, 1992.
18. Holzmann B, Gosslar U and Bittner M: alpha 4 integrins and tumor metastasis. Curr Top Microbiol Immunol 231: 125-141, 1998.
19. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, Yamada SD and Lengyel E: Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 68(7): 2329-2339, 2008.
20. Takayama S, Ishii S, Ikeda T, Masamura S, Doi M and Kitajima M: The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Res 25(1a): 79-83, 2005.
21. Wewer UM, Shaw LM, Albrechtsen R and Mercurio AM: The integrin alpha 6 beta 1 promotes the survival of metastatic human breast carcinoma cells in mice. Am J Pathol 151(5): 1191-1198, 1997.
22. Shibue T and Weinberg RA: Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci USA 106(25): 10290-10295, 2009.
23. Lu X, Lu D, Scully M and Kakkar V: The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy. Perspect Medicin Chem 2: 57-73, 2008.
24. Roman J, Ritzenthaler JD, Roser-Page S, Sun X and Han S: alpha5beta1-integrin expression is essential for tumor progression in experimental lung cancer. Am J Respir Cell Mol Biol 43(6): 684-691, 2010.
25. Schaffner F, Ray AM and Dontenwill M: Integrin alpha5beta1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors. Cancers 5(1): 27-47, 2013.
26. Schlaepfer DD, Mitra SK and Ilic D: Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 1692(2-3): 77-102, 2004.
27. Xue G and Hemmings BA: PKB/Akt-dependent regulation of cell motility. J Natl Cancer Inst 105(6): 393-404, 2013.
28. Sieg DJ, Hauck CR, Schlaepfer DD: Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci 112(Pt 16): 2677-2691, 1999.
29. Spiering D and Hodgson L: Dynamics of the Rho-family small GTPases in actin regulation and motility. Cell Adh Migr 5(2): 170-180, 2011.
30. OConnor K and Chen M: Dynamic functions of RhoA in tumor cell migration and invasion. Small GTPases 4(3): 141-147, 2013.
31. Parri M, Chiarugi P: Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal 8: 23, 2010.
32. Yamazaki D, Kurisu S and Takenawa T: Regulation of cancer cell motility through actin reorganization. Cancer Sci 96(7): 379-386, 2005.
33. Nobes CD and Hall A: Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81(1): 53-62, 1995.
34. Burridge K and Chrzanowska-Wodnicka M: Focal adhesions, contractility, and signaling. Annu Rev Cell Dev Biol 12: 463-518, 1996.